Patent for Treating MASLD and MASH Using OCT4, SOX2, KLF4
Summary
The USPTO published patent application US20260108630A1 on April 23, 2026, disclosing methods for treating metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH) by administering one or more nucleic acids encoding OCT4, SOX2, and KLF4 transcription factors. The application claims the administration may rejuvenate hepatocytes or liver stellate cells and improve symptoms of the liver disease. The four named inventors are Sharon Rosenzweig-Lipson, Ming Yang, Richard Davis, and Michel Wathier, with Application No. 19360504 filed on October 16, 2025.
“Provided are methods for treating a subject with a liver disease such as metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH).”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
The USPTO published a patent application disclosing gene therapy methods for treating MASLD and MASH using partial epigenetic reprogramming. The application claims methods comprising administering nucleic acids encoding OCT4, SOX2, and KLF4 transcription factors to a subject with liver disease, with the stated aim of rejuvenating hepatocytes or liver stellate cells and improving disease symptoms.
Pharmaceutical and biotechnology companies developing gene therapies for liver diseases should review this application to assess competitive landscape in the OCT4/SOX2/KLF4 reprogramming space. The CPC classifications (A61K 48/005, A61K 38/1709, A61K 48/0075, A61P 1/16) indicate the application falls within nucleic acid-based therapies targeting liver conditions.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PARTIAL EPIGENETIC REPROGRAMMING FOR LIVER DISEASE TREATMENT
Application US20260108630A1 Kind: A1 Apr 23, 2026
Inventors
Sharon Rosenzweig-Lipson, Ming Yang, Richard Davis, Michel Wathier
Abstract
Provided are methods for treating a subject with a liver disease such as metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). The method may include administering to the subject one or more nucleic acids encoding OCT4, SOX2 and KLF4. The administration may rejuvenate hepatocytes or liver stellate cells in the subject, and may improve a symptom of the liver disease.
CPC Classifications
A61K 48/005 A61K 38/1709 A61K 48/0075 A61P 1/16
Filing Date
2025-10-16
Application No.
19360504
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.